Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI353 (Orismilast) Safety and PK in Healthy Chinese Subjects
NCT05490316Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orismilast in psoriasis and atopic dermatitis (AD) (3 arms), sponsored by Innovent Biologics. Primary endpoints: Time to Maximal Blood Concentration, Maximal Concentration and 5 more. Started Nov 2022; status: completed.
02
Drugs
orismilast
03
Conditions
psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05490316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490316.